ABBV
Price
$229.13
Change
-$1.17 (-0.51%)
Updated
Oct 14 closing price
Capitalization
404.77B
16 days until earnings call
Intraday Buy/Sell Signals
BIIB
Price
$145.31
Change
+$0.62 (+0.43%)
Updated
Oct 14 closing price
Capitalization
21.3B
15 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ABBV vs BIIB

Header iconABBV vs BIIB Comparison
Open Charts ABBV vs BIIBBanner chart's image
ABBVIE
Price$229.13
Change-$1.17 (-0.51%)
Volume$5.53M
Capitalization404.77B
Biogen
Price$145.31
Change+$0.62 (+0.43%)
Volume$1.28M
Capitalization21.3B
ABBV vs BIIB Comparison Chart in %
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. BIIB commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and BIIB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (ABBV: $229.13 vs. BIIB: $145.31)
Brand notoriety: ABBV and BIIB are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 98% vs. BIIB: 78%
Market capitalization -- ABBV: $404.77B vs. BIIB: $21.3B
ABBV [@Pharmaceuticals: Major] is valued at $404.77B. BIIB’s [@Pharmaceuticals: Major] market capitalization is $21.3B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $728.24B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $93.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green whileBIIB’s FA Score has 0 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • BIIB’s FA Score: 0 green, 5 red.
According to our system of comparison, ABBV is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 3 TA indicator(s) are bullish while BIIB’s TA Score has 5 bullish TA indicator(s).

  • ABBV’s TA Score: 3 bullish, 5 bearish.
  • BIIB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than BIIB.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а -1.59% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -4.53% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.73%. For the same industry, the average monthly price growth was +0.78%, and the average quarterly price growth was +19.32%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 31, 2025.

BIIB is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.73% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($405B) has a higher market cap than BIIB($21.3B). ABBV has higher P/E ratio than BIIB: ABBV (109.11) vs BIIB (13.91). ABBV YTD gains are higher at: 32.495 vs. BIIB (-4.976). ABBV has higher annual earnings (EBITDA): 14.2B vs. BIIB (2.79B). ABBV has more cash in the bank: 6.47B vs. BIIB (2.76B). BIIB has less debt than ABBV: BIIB (6.6B) vs ABBV (70.5B). ABBV has higher revenues than BIIB: ABBV (58.3B) vs BIIB (10B).
ABBVBIIBABBV / BIIB
Capitalization405B21.3B1,901%
EBITDA14.2B2.79B508%
Gain YTD32.495-4.976-653%
P/E Ratio109.1113.91785%
Revenue58.3B10B583%
Total Cash6.47B2.76B234%
Total Debt70.5B6.6B1,069%
FUNDAMENTALS RATINGS
ABBV vs BIIB: Fundamental Ratings
ABBV
BIIB
OUTLOOK RATING
1..100
7668
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
90
Overvalued
PROFIT vs RISK RATING
1..100
7100
SMR RATING
1..100
1374
PRICE GROWTH RATING
1..100
1451
P/E GROWTH RATING
1..100
1463
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABBV's Valuation (90) in the Pharmaceuticals Major industry is in the same range as BIIB (90) in the Biotechnology industry. This means that ABBV’s stock grew similarly to BIIB’s over the last 12 months.

ABBV's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than BIIB’s over the last 12 months.

ABBV's SMR Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (74) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than BIIB’s over the last 12 months.

ABBV's Price Growth Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (51) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than BIIB’s over the last 12 months.

ABBV's P/E Growth Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (63) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVBIIB
RSI
ODDS (%)
Bearish Trend 1 day ago
32%
Bearish Trend 1 day ago
62%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 1 day ago
68%
Momentum
ODDS (%)
Bearish Trend 1 day ago
39%
Bullish Trend 1 day ago
58%
MACD
ODDS (%)
Bearish Trend 1 day ago
36%
Bearish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
43%
Bearish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
59%
Advances
ODDS (%)
Bullish Trend 14 days ago
58%
Bullish Trend 12 days ago
56%
Declines
ODDS (%)
Bearish Trend 1 day ago
43%
Bearish Trend 2 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
40%
Bearish Trend 1 day ago
65%
Aroon
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
50%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KXI64.870.80
+1.25%
iShares Global Consumer Staples ETF
NRO3.21N/A
+0.16%
Neuberger Berman Real Estate Sec Income Fund
BEMB53.99-0.02
-0.04%
iShares J.P. Morgan Brd USD Emr MktBdETF
GFLW28.36-0.19
-0.66%
VictoryShares Free Cash Flow Growth ETF
SCHG31.77-0.27
-0.84%
Schwab US Large-Cap Growth ETF™